Lung cancer is the leading cause of cancer-related deaths worldwide. Immune checkpoint
inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and …

Abstract Programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells
accelerates tumor progression. PD-L1 possesses two main pro-oncogenic functions. First …

The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing
oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions …

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal
hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately …

Abstract microRNAs (miRNAs) play critical roles in cancer development and progression.
This study investigated the effects of miR-138-5p in human colorectal cancer (CRC) …

The programmed cell death protein 1 (PD-1) limits effector T-cell functions in peripheral
tissues, and its inhibition leads to clinical benefit in different cancers. To better understand …

Blockade of the immune checkpoint PD-1/PD-L1 with monoclonal antibodies demonstrated
unprecedented clinical efficacies in many cancers. But the orally available low molecular …

PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1
blockade anticancer therapies, particularly for lung cancer. However, the reliability of this …

Cancer immunotherapies targeting immune checkpoints such as programmed cell-death
protein 1 (PD-1) and its ligand programmed cell-death 1 ligand 1 (PD-L1), are …

Since the beginning of the 20th century, scientists have tried to stimulate the antitumour
activities of the immune system to fight against cancer. However, the scientific effort devoted …